Pharmacokinetics of Long-Acting Preparations of Telacebec
- Institution
- SOUTHERN RESEARCH INSTITUTE, AL
- Principal investigator
- Raymond Bronner
- Funding
- $15K
- Duration
- 2024–2025
Moonbase score
Still being scored
Abstract
Preclinical Services for HIV Therapeutics: The purpose of these Indefinite Delivery/Indefinite Quantity contracts is to provide the extramural scientific community with research materials and preclinical product development support for candidate products that emerge from investigator-initiated research studies or from collaborations with private sector or academic partners. The scope of work encompasses activities that range from basic research and initial product discovery to activities required for clinical trials and/or product licensure. These services may also be used to support product discovery and development leading to Investigational New Drug Application (IND), Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the Food and Drug Administration (FDA). NIAID Division of AIDS will primarily use these contracts to fill critical development and resource gaps more rapidly and efficiently and advance promising products into clinical testing. The purpose of this task order is to determine the pharmacokinetics (PK) of long-acting preparations of Telacebec (Q203) in Sprague Dawley Rats.
LOADING MOONBASE SCORE
Questions for SOUTHERN RESEARCH INSTITUTE
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · Southern Research InstituteNot yet scored
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
Mohammad Athar · $805K · 2023–2026
- NIH · Southern Research InstituteNot yet scored
Task B23: Medicinal Chemistry and Problem Solving Synthesis for Antivirals
Dr. Corinne Augelli-Szafran · $346K · 2021–2025
- NIH · Research Triangle InstituteNot yet scored
HIV Assay Development and Testing to Identify Targeted Activator of Cell Kill Molecules
Rangan Maitra · $1.1M · 2024–2026